- Definitive radiation therapy (DRT) to limited sites in patients with oligometastatic cervical cancer (CC) yields favorable outcomes with potential long-term survival benefit.
- At 2 y post-RT, approximately half of the patients had disease progression with minimal toxicity.
Why this matters
- In patients with regional CC who progress to metastatic disease, systemic chemotherapy offers median survival of <1 to 2 y.
- Although chemotherapy is the current treatment of choice, DRT may be more effective and safe in this patient population.
- Study of 38 patients with oligometastatic CC involving ≤2 extra-pelvic/para-aortic sites, receiving external-beam DRT and brachytherapy with concurrent chemotherapy or surgical resection..
- Oligometastasis included synchronous (n=9) or metachronous (n=15) disease to supraclavicular nodes or recurrence in mediastinum (n=10), lung (n=7), or supraclavicular+mediastinal sites (n=3).
- Median follow-up, 35.2 mo (range 3.1-94.7).
- Funding: National Institute of Cancer.
- Median OS was 50.7 mo (95% CI, 36.8-64.6 mo); 2- and 3-y OS rates were 73.5% and 63.7%, respectively.
- 18 and 6 patients had survived >3 and >5 y, respectively.
- Median PFS was 21.7 mo (95% CI, 5.6-37.8 mo).
- 55% patients progressed; median time to progression was 24.8 mo (95% CI, 5.0-44.6 mo).
- Treatment-associated grade ≥3 toxicity was <3%.
- Highly selected and small study population.